Impact to Date
A Race Against Blindness has paid out $7.1M in research grants to two complementary paths: advancing AXV-101, a targeted investigational BBS1 therapy, and expanding gene-agnostic research designed to help more families.
$7.1 million supporting two complementary paths
$5.1M has been paid toward AXV-101, a targeted investigational therapy for vision loss associated with BBS1. $2M has been paid toward gene-agnostic approaches intended to reach patients across many inherited retinal diseases.
One commitment advances an investigational therapy created for BBS1 toward clinical study. The other expands therapeutic approaches that may help patients regardless of the gene causing their inherited retinal disease.
$5.1 million paid toward AXV-101
AXV-101 is an investigational therapy aimed at treating vision loss associated with Bardet-Biedl syndrome 1. RAB's funding has supported the program as it moved toward a first clinical study.
The final $1.1 million award closed the remaining funding gap identified for planned clinical trial initiation and brought RAB's total AXV-101 commitment to $5.1 million. The program received Clinical Trial Application clearance in the third quarter of 2025. The January 2026 update reported that trial initiation was expected in early 2026.
Project reference: AXV-101 funding announcement
$2 million expanding gene-agnostic research
Gene-agnostic approaches are intended to work independently of a patient's specific disease-causing mutation. RAB's two grants paid to the Foundation Fighting Blindness in June and November 2026 support a portfolio of therapeutic programs and two academic research awards focused on retinal gene therapy delivery and retinal regeneration.
$1,475,000 building a broader therapeutic portfolio
Funding directed to the Gund Vision Fund (formerly the RD Fund) supports gene-agnostic programs across its portfolio, including neuroprotective and antioxidant strategies intended to slow retinal degeneration and vision-restoration approaches such as optogenetics.
Both gifts were matched dollar for dollar through the Gordon and Llura Gund Foundation Challenge, bringing the amount directed to the Fund to $2.95 million.
$225,000 advancing a new delivery approach
This funding completed a five-year, $375,000 Career Development Award supporting Dr. Thomas Mendel at The Ohio State University Wexner Medical Center. His preclinical work studies delivery of gene therapy onto the retinal surface, combined with insulin to accelerate uptake into retinal cells.
The gene-agnostic method may have relevance across conditions including BBS, choroideremia, Leber congenital amaurosis, Stargardt disease, Usher syndrome, and multiple forms of retinitis pigmentosa.
Project reference: Gene-agnostic research funding announcement
$300,000 regenerating the retina from within
This award supports Dr. Jin Woo Kim at the Korea Advanced Institute of Science and Technology (KAIST). His preclinical research uses an antibody to block PROX1, a protein that normally keeps Müller glia, the retina's support cells, from regenerating. With PROX1 blocked, Müller glia can reprogram into progenitor-like cells, immature cells that may develop into new light-sensing photoreceptors. In animal models of retinitis pigmentosa, the approach has restored visual function.
Because it works by promoting retinal repair, not by correcting a single gene, it may have relevance across many forms of RP. The award will refine the antibody and its delivery and move the most durable candidates toward large-animal studies.
